Abstract
Purpose :
Trypan blue (TB) 0.15% was supplied by a compounding pharmacy to surgeons in the area for six years. After six years, the pharmacy informed the surgeons that there had been a systematic error in the production of TB 0.15% resulting in the production of TB 1.5%, a ten-fold increase in the FDA approved concentration. The goal of the study is to evaluate the outcomes, efficacy, and complication rates of the use of Trypan blue 1.5% in vitreomacular surgery.
Methods :
A consecutive retrospective chart review of subjects 18 years or older who had undergone Trypan blue 1.5% assisted vitreomacular surgery for macular pucker or macular hole between 2009 to 2012 was performed. Patients with a history of intraocular surgery were excluded with the exception of uncomplicated clear cornea cataract extraction. The primary outcomes were retinal anatomy based on OCT images (decreased central thickness, macular hole closure) and Best Corrected Visual Acuity (BCVA).
Complication and adverse event rates were analyzed.
Results :
351 patients undergoing surgery by two primary surgeons are included. The difference between preoperative and post operative visual acuity 2.39 ± 4.49 lines, p<0.0001. 84.3% of macular holes closed. There was no toxicity or complications reported.
Conclusions :
Visual outcomes and surgical success rate with TB 1.5% are similar to the reported rates from the use of TB 0.15%.
This abstract was presented at the 2019 ARVO Imaging in the Eye Conference, held in Vancouver, Canada, April 26-27, 2019.